Navigation Links
Pharmasset Announces Two-for-One Forward Stock Split
Date:8/9/2011

PRINCETON, N.J., Aug. 9, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend.  Stockholders of record as of the close of business on August 22, 2011 will receive one additional share of common stock for each share then owned.  The distribution date for the new shares will be August 31, 2011.  There are currently approximately 37.7 million shares of common stock outstanding.  Upon completion of the stock split, there will be approximately 75.4 million shares of common stock outstanding.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.  Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection.  Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.  We currently have three clinical-stage product candidates advancing in trials in various populations.  Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in four Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens.  Our purine, PSI-938, an unpartnered guanosine nucleotide analog, reported safety and efficacy data from 14 days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977.  An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third calendar quarter of 2011.  Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk that the stock split does not occur, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... Forum which featured keynote addresses by Donald W. Rucker, MD, head of the ...
(Date:8/23/2017)... ... ... Nightingale College continues the semiannual Give Back Day tradition for its fourth year ... serving and volunteering for organizations that provide indispensable resources to the community. The College ... little extra help. , The College’s Give Back Day initiative began in 2013 ...
(Date:8/23/2017)... Elkhart, Indiana (PRWEB) , ... August 23, 2017 ... ... Whitney Boling, MD , has returned home to Indiana, and is now ... Boling is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC ... Awards® - for Risk Management Solution Innovations and Security Solution for Government Innovations. ... released in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , ...
(Date:8/22/2017)... ... 22, 2017 , ... The Women’s Choice Award, a growing platform that gives ... 2017 Women’s Choice Award. The identification by women of an effective new migraine ... sufferers are women. In a survey taken by the Women’s Choice Award organization, nine ...
Breaking Medicine News(10 mins):